Strong Sales and Profit Growth
Novo Nordisk achieved a 15% sales growth and a 10% operating profit growth for the first 9 months of 2025.
Expansion in Obesity Care
Obesity care sales increased by 41%, with significant growth in international operations by 83%.
Launch of Wegovy Pill
Novo Nordisk is preparing for the launch of the Wegovy pill in the U.S., with potential launches in selected international markets.
Strategic Acquisitions
Novo Nordisk announced acquisitions of Akero and Omeros' zaltenibart assets to strengthen their pipeline in diabetes and obesity.